Drug Trial Radar · NCT07519772
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
May 3, 2026
Primary completion
Jul 1, 2030
Study completion Apr 1, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system. In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer. The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.
Conditions
- Lymphoma, Non-Hodgkin
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
Interventions
MK-1045Biological
Intravenous (IV) Infusion or Subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 49 months
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 12 months
- Arms 2 and 3: Number of Participants Who Experience Dose Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
- Arms 1, 2, and 4: Objective Response Rate (ORR) per Lugano Response Criteria as assessed by Blinded Independent Central review (BICR)Time frame: Up to approximately 49 months
Locations
56 sites in 16 countries. Site status is shown where the registry gives one.
Cedar Sinai Cancer Center ( Site 0119)
Los Angeles, California · Recruiting
Colorado Blood Cancer Institute ( Site 7000)
Denver, Colorado · Recruiting
University Hospitals of Cleveland ( Site 0113)
Cleveland, Ohio · Recruiting
SCRI Oncology Partners ( Site 0100)
Nashville, Tennessee · Recruiting
Henry-Joyce Cancer Clinic ( Site 0115)
Nashville, Tennessee · Recruiting
Hospital Aleman ( Site 1400)
CABA, Argentina · Recruiting
Instituto Alexander Fleming ( Site 1404)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Hospital Universitario Austral ( Site 1402)
Pilar, Buenos Aires, Argentina · Recruiting
Sanatorio Nuestra Senora del Rosario ( Site 1403)
Rosario, Santa Fe Province, Argentina · Recruiting
Townsville University Hospital ( Site 0204)
Townsville, Queensland, Australia · Recruiting
Royal Adelaide Hospital ( Site 0205)
Adelaide, South Australia, Australia · Recruiting
Box Hill Hospital ( Site 0202)
Box Hill, Victoria, Australia · Recruiting
Hospital Paulistano ( Site 1504)
São Paulo, Brazil · Recruiting
Hospital Erasto Gaertner ( Site 1503)
Curitiba, Paraná, Brazil · Recruiting
Hospital das Clinicas FMUSP ( Site 1502)
São Paulo, São Paulo, Brazil · Recruiting
Princess Margaret Cancer Centre ( Site 0301)
Toronto, Ontario, Canada · Recruiting
Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0305)
Montreal, Quebec, Canada · Recruiting
Clínica Alemana de Santiago ( Site 1608)
Santiago, Region M. de Santiago, Chile · Recruiting
Pontificia Universidad Catolica de Chile-CICUC ( Site 1603)
Santiago, Region M. de Santiago, Chile · Recruiting
Beijing Cancer hospital ( Site 1701)
Beijing, Beijing Municipality, China · Recruiting
Fujian Provincial Cancer Hospital.. ( Site 1704)
Fuzhou, Fujian, China · Recruiting
Sun Yat-Sen University Cancer Center ( Site 1712)
Guangzhou, Guangdong, China · Recruiting
Henan Cancer Hospital ( Site 1702)
Zhengzhou, Henan, China · Recruiting
Fudan University Shanghai Cancer Center ( Site 1711)
Shanghai, Shanghai Municipality, China · Recruiting
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0400)
Nice, Alpes-Maritimes, France · Recruiting
Hopital Saint Louis ( Site 0405)
Paris, Île-de-France Region, France · Recruiting
CHU Estaing ( Site 0403)
Clermont-Ferrand, Puy-de-Dome, France · Recruiting
UKGM Gießen/Marburg ( Site 0505)
Giessen, Hesse, Germany · Recruiting
Universitatsklinikum Essen AoR ( Site 0507)
Essen, North Rhine-Westphalia, Germany · Recruiting
Carmel Hospital ( Site 0602)
Haifa, Israel · Recruiting
Shaare Zedek Medical Center ( Site 0603)
Jerusalem, Israel · Recruiting
Haddasah Medical Center ( Site 0600)
Jerusalem, Israel · Recruiting
Sheba Medical Center ( Site 0601)
Ramat Gan, Israel · Recruiting
Sourasky Medical Center. ( Site 0604)
Tel Aviv, Israel · Recruiting
Istituto Europeo di Oncologia IRCCS ( Site 0702)
Milan, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli ( Site 0705)
Roma, Italy · Recruiting
Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Ematologia Oncologica ( Site 0700)
Campania, Napoli, Italy · Recruiting
INOC - Istituto Nazionale Oncologico Candiolo ( Site 0701)
Candiolo, Piedmont, Italy · Recruiting
Pratia MCM Krakow ( Site 0903)
Krakow, Lesser Poland Voivodeship, Poland · Recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 0900)
Warsaw, Masovian Voivodeship, Poland · Recruiting
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.